Company news
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) news
Artiva Biotherapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American…
Press releases & updates
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
October 1, 2026
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
September 30, 2026
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
September 23, 2026
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
September 8, 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 2, 2026
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
June 7, 2026
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 18, 2026
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 10, 2026
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
February 23, 2026
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 18, 2026
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
January 21, 2026
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
November 12, 2025
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
November 3, 2025
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
October 30, 2025
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
October 16, 2025
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
August 25, 2025
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
August 6, 2025
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
May 13, 2025
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
May 8, 2025
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
April 28, 2025
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
April 8, 2025
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
March 24, 2025
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
February 20, 2025
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
January 28, 2025
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 11, 2024
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
October 21, 2024
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 28, 2024